Facsimile Signatures Clause Example with 5 Variations from Business Contracts

Facsimile Signatures. This Warrant may be executed by facsimile signature. [remainder of page intentionally left blank] EXECUTED as of the Date of Issuance indicated above. LYRA THERAPEUTICS, INC. By: Name: Maria Palasis, Ph.D. Title: Chief Executive Officer EXHIBIT I PURCHASE FORM To:_________________ Dated:____________ The undersigned, pursuant to the provisions set forth in the attached Warrant (No. ___), hereby elects to purchase (check applicable box): ☐ ____ shares of the Common Stock of Lyra Therapeutics, Inc.... covered by such Warrant; or ☐ the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth in subsection 1(b). The undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant. Such payment takes the form of (check applicable box or boxes): ☐ $______ in lawful money of the United States; and/or ☐ the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 1(b), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(b). Signature: Address: EXHIBIT II ASSIGNMENT FORM FOR VALUE RECEIVED, ________________________________________ hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant (No. ____) with respect to the number of shares of Common Stock of Lyra Therapeutics, Inc. covered thereby set forth below, unto: Name of Assignee Address and Electronic Mail Address No. of Shares Dated:_____________________ Signature:___________________________________________ Signature Guaranteed: By: _______________________ EX-4.2 3 d323142dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 LYRA THERAPEUTICS, INC. Schedule of Holders of Warrants to Purchase Common Stock Holder WarrantNo. Number ofShares Venrock Healthcare Capital Partners EG, L.P. PFCS-1 1,956,500 Venrock Healthcare Capital Partners III, L.P. PFCS-2 1,739,000 VHCP Co-Investment Holdings III, LLC PFCS-3 174,000 Venrock Healthcare Capital Partners II, L.P. PFCS-4 804,500 VHCP Co-Investment Holdings II, LLC PFCS-5 326,000 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. PFCS-[•] Number of Shares: [•] (subject to adjustment) Date of Issuance: April 12, 2022 Original Issue Date (as defined in subsection 2(a)): April 12, 2022 Lyra Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m. (New York City time) on April 12, 2027) Lyra Therapeutics, Inc., a Delaware corporation (the "Company"), for value received, hereby certifies that [•], or its registered assigns (the "Registered Holder"), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York City time) on April 12, 2027, shares of Common Stock, $0.001 par value per share, of the Company ("Common Stock"), at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the "Warrant Shares" and the "Purchase Price," respectively. This Warrant is one of the Common Stock Purchase Warrants (the "Warrants") issued pursuant to that certain Securities Purchase Agreement, dated as of April 7, 2022, by and among the Company and each of the investors party thereto (the "Purchase Agreement"). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein. View More